Bloomberg Law
July 5, 2022, 7:19 AM

Astra Agrees to Pay up to $1.3 Billion for Biotech TeneoTwo (1)

Marthe Fourcade
Marthe Fourcade
Bloomberg Editorial

AstraZeneca Plc agreed to buy the closely held US biotech TeneoTwo Inc. for as much as $1.3 billion, almost all of it in milestone payments, to gain an experimental drug for lymphomas.

The medicine, called TNB-486, is in early-stage clinical trials, Astra said in a statement Tuesday. It belongs to a class of therapeutic antibodies known as T-cell engagers -- molecules engineered to redirect the immune system’s T-cells to recognize and kill cancer cells.

AstraZeneca has been pushing ahead to expand its treatment offering in cancer and said the new medicine could build on the success of Calquence, its leukemia ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.